Novel transaminase and application thereof in synthesis of remegapam

Through the enzyme-catalyzed reaction based on Aquamicrobium defluvii aminotransferase, the problems of stereoselectivity and low yield in the synthesis of Ruimeijipan intermediates were solved, and efficient and green intermediate synthesis was achieved, with significantly improved product purity and yield, suitable for industrialization Production.

CN119020312APending Publication Date: 2024-11-26ZHEJIANG HONGYUAN PHARMA +1

Patent Information

Application Number
CN202411254564.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-09
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Existing Remeji Pan key intermediate (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cycloheptane [b]There are stereoselectivity problems in the synthesis of pyridin-9-ol, resulting in low yields and low quality. The traditional methods use highly toxic and explosive chemicals, which increases the risk of industrial production.

Method used

Using high stereoselective aminotransferase based on Aquamicrobium defluvii source, the Rymejipan intermediate was generated through enzyme catalytic reaction, and trimethylolamide aminomethane, isopropylamine and pyridoxal phosphate were used as auxiliary agents to control the reaction conditions such as pH value and Temperature, improve product purity and yield.

Benefits of technology

It has achieved efficient synthesis of Ruimeijipan intermediates, with the optical purity of the product reaching 99.96%, and the yield reaches more than 90%. The process is simple and green, and the use of toxic and dangerous reagents is avoided, and it is suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The invention provides a novel mutant based on a source Aquammicrobium defluvii transaminase ADTA (aminotransferase), and the novel mutant is a novel aminotransferase. According to the aminotransferase, efficient synthesis of the remegapam intermediate (5S, 6S, 9R)-5-amino-6-(2, 3-difluorophenyl)-6, 7, 8, 9-tetrahydro-5H-cycloheptane [b] pyridine-9-alcohol is achieved, and the remegapam intermediate (5S, 6S, 9R)-5-amino-6-(2, 3-difluorophenyl)-6, 7, 8, 9-tetrahydro-5H-cycloheptane [b] pyridine-9-alcohol is easy and convenient to operate, environmentally friendly, high in yield and good in stereoselectivity. In addition, the transaminase catalysis method provided by the invention is low in preparation cost and mild in reaction condition, and is a biological catalysis technology more suitable for industrial production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of organic chemistry and bioengineering, and relates to a novel transaminase and its application in the synthesis of Remigipam. More specifically, the present invention relates to a novel mutant of transaminase derived from Aquamicrobium defluvii, and its application in the synthesis of the key intermediate of Remigipam (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine-9-ol. Background Art

[0002] Migraine is a pulsating headache that occurs periodically on one or both sides and is a common primary headache in clinical practice. Migraine patients experience severe headaches, accompanied by symptoms such as nausea, vomiting, and fear of light, which can last for 4 to 72 hours. They are often accompanied by neurological and mental disorders before or during the headache. Migraine is caused by the stimulation of the pain receptors in the head and neck, which produces abnormal nerve impulses and transmits them to the brain. Its etiology is relatively complex. Intracranial, extracranial, and head and neck lesions, other neuroses, and mental illnesses may all cause migraine. Due to its high incidence and significant impact on society and individuals, it has been regarded as the third most prevalent disease in the world.

[0003] Migraine symptoms are often treated with triptan serotonin / 5-HT receptor agonists (eg, sumatriptan), which come in a variety of formulations, including tablets, subcutaneous injections, and nasal sprays, each with a specific onset and duration. However, these agents are not always effective in relieving symptoms, and their specific mechanisms of action are unclear and remain speculative in most cases.

[0004] In recent years, with the in-depth research on migraine at home and abroad, there has been significant progress in its treatment field, especially the discovery of new therapeutic targets such as calcitonin gene-related peptide (CGRP), which provides new treatment options for migraine patients. Calcitonin gene-related peptide (CGRP) is a neuropeptide composed of 37 amino acids, which plays an important role in various physiological processes such as cardiovascular homeostasis and pain perception regulation. In the pathogenesis of migraine, CGRP participates in regulating the process of migraine attacks by dilating blood vessels, promoting neuroinflammation, and transmitting pain signals. CGRP antibody drugs can effectively block the effects of CGRP, thereby reducing the frequency and severity of migraine attacks. Compared with early drugs (such as triptans), CGRP targeted drugs have been proven to be effective and have fewer side effects. Therefore, the treatment strategy targeting CGRP has become one of the important means of treating migraine.

[0005] At present, with further research and clinical practice, new preventive anti-migraine therapeutic drugs targeting CGRP or its receptors are constantly coming out, including small molecule CGRP receptor antagonists and monoclonal antibodies targeting CGRP or its receptors, which have been approved by FDA / EMA for the preventive treatment of migraine in adults. Here, seven CGRP receptor blockers have been developed for the treatment of migraine, of which four have been discontinued due to disadvantages such as low oral bioavailability and hepatotoxicity. In contrast, rimegepant, ubrogepant, and atogepant are small molecule CGRP receptor antagonists for oral administration that have been approved by the FDA for the acute or preventive treatment of migraine, of which rimegepant is undergoing clinical trials to obtain approval as an innovative drug for preventive treatment. Remegepant has the characteristics of convenient administration, rapid onset of action, and long duration of efficacy. Its chemical structure is shown in the figure below:

[0006]

[0007] In 2020, Biohaven was approved by the US FDA to launch the first oral fast-disintegrating tablet-type CGRP small molecule receptor antagonist, which can be used to treat and prevent acute migraine in adults. Therefore, as the first oral CGRP small molecule receptor antagonist, Remigipam will have certain development prospects in the future. The synthesis route of Remigipam is reported in detail in patents W02011046997A and WO2012050764A. In the disclosed technical routes, the chiral substance (5S, 6S, 9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cycloheptan and [b] pyridine-9-ol is involved, as shown in Formula I, which is the key intermediate in the synthesis route of Remigipam. Therefore, the preparation method of this intermediate has become the focus of Remigipam research.

[0008]

[0009] The synthesis of (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cycloheptan[b]pyridine-9-ol is usually carried out by reductive amination. For example, the compound of formula II is prepared into its imine derivative, and then converted into the corresponding amine product by reduction, as shown in Scheme 1. However, the reduction process often has stereoselectivity problems, resulting in the production of its isomer (5R,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cycloheptan[b]pyridine-9-ol (as shown in Formula I-1), which greatly reduces the yield of the key intermediate, and thus also affects the quality of Remigipam.

[0010]

[0011] Solution 1

[0012]

[0013] A common method to solve this problem is to select appropriate amines and reducing agents to improve the stereoselectivity of the target product. In patent WO2011046997A, Bristol-Myers Squibb mentioned that compound IV is used as a raw material to generate intermediate V, an analog of compound I, through reduction, chlorination, and azide reactions, as shown in Scheme 2. The reaction steps in this patent are numerous and cumbersome, and a large number of chiral impurities are introduced during the synthesis process, resulting in lower quality of the final product. In addition, the process uses highly toxic and explosive chemicals such as sodium azide, which brings greater EHS risks to industrial production.

[0014]

[0015] Solution 2

[0016] Similarly, the patent introduces another preparation method of Remigipam, as shown in Scheme 3. The synthesis method of intermediate V-1: Compound IV is used as a raw material, tetraisopropoxytitanium is used to catalyze the generation of an imine intermediate, which is then hydrogenated to an amino group by palladium catalysis, and the carbonyl group is converted to an amino group by an amination reaction. The product yield obtained in this process is low, and the post-processing steps are complicated, which seriously affects the yield of the final product Remigipam.

[0017]

[0018] Option 3

[0019] Nanjing Aidekaiteng Biopharmaceutical Co., Ltd. also reported a method for preparing Remigipam intermediate V in patent CN116768938A, as shown in Scheme 4. 2+ In the presence of EDTA / EDTA catalyst, a mixture of intermediates V was obtained by asymmetric reduction amination, and then dextrorotatory camphorsulfonic acid was used as a chiral resolution agent to prepare a chiral amine analogue of the key intermediate of Remigipam (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine-9-ol with a single configuration, as shown in Scheme 4.

[0020]

[0021] Option 4

[0022] However, the whole process of the patent is complicated, and the HPLC purity of the obtained intermediate V is only 98.0%, and the yield is low.

[0023] Nanchang Changyou Pharmaceutical Technology Co., Ltd. has a patent CN115677694A involving the synthesis process of the intermediate (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine-9-ol, as shown in Scheme 5. In this patent, the carbonyl group is converted into an amino group through an enzyme-catalyzed asymmetric reduction reaction under the action of a biotransaminase. The de value of the target product obtained after purification in this patent is 99.3-99.5%, and the yield is not high.

[0024]

[0025] Option 5

[0026] Jiao et al. reported in the literature (Org. Process Res. Dev. 2022, 26, 1971-1977) the enzymatic synthesis route of the intermediate (5S, 6S, 9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cycloheptan and [b] pyridine-9-ol shown in formula I. Under the catalysis of the transaminase variant M20, the compound of formula II is reacted in one step to generate the intermediate compound of formula I. The transaminase has high activity on the substrate, and the purity of the intermediate generated by the reaction can reach 99.85%. However, the yield of the product is low, the preparation process of the enzyme is complicated, and its activity and stability need to be improved.

[0027] It can be seen that the synthesis of drug intermediates by enzymatic methods can provide higher yields and fewer by-products than traditional chemical synthesis routes. Transaminases are increasingly used as biocatalysts for the synthesis of drug intermediates, which can achieve efficient and specific chemical reactions. Transaminase-catalyzed transamination of ketone compounds to generate corresponding chiral amines in a single-step reaction has gradually become the preferred and commonly used method in the pharmaceutical field. However, its main disadvantage is its poor substrate acceptance, which limits the synthesis of sterically hindered chiral amines.

[0028] Based on the shortcomings of the current synthesis process of the intermediate (5S, 6S, 9R) -5-amino-6- (2, 3-difluorophenyl) -6, 7, 8, 9-tetrahydro -5H- cycloheptan and [b] pyridine -9-ol of Remigipan, it is urgent to develop a biocatalytic method that is simple to operate, green and environmentally friendly, has a high yield, and is suitable for industrial-scale production. Here, the present invention uses a transaminase catalyzed with high stereoselectivity to achieve the efficient synthesis of the intermediate (5S, 6S, 9R) -5-amino-6- (2, 3-difluorophenyl) -6, 7, 8, 9-tetrahydro -5H- cycloheptan and [b] pyridine -9-ol of Remigipan, with high product yield and de value, good enzyme selectivity, low synthesis cost, and suitable for industrial-scale production. Summary of the invention

[0029] In order to solve the shortcomings of the above technical route, the present invention provides a transaminase for synthesizing the key intermediate of Remigipan (5S, 6S, 9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine-9-ol, and the transaminase mainly includes the following characteristics:

[0030] A transaminase, characterized in that the amino acid sequence is the protein shown in SEQ ID NO: 1.

[0031] The transaminase described in the present invention is characterized in that the gene encoding the transaminase is the nucleotide sequence shown in SEQ ID NO: 2.

[0032] The recombinant expression vector, transgenic cell line or host bacteria of the transaminase encoding gene described in the present invention.

[0033] The invention discloses an application of the transaminase in synthesizing a key intermediate of Remigipam.

[0034] The use of the transaminase in the synthesis of the key intermediate of Remigipam in the present invention is characterized by comprising the following steps: the compound of formula II reacts under the action of the transaminase to generate the compound of formula I, and the reaction formula is as follows:

[0035]

[0036] The use of the transaminase described in the present invention in the synthesis of the key intermediate of Remigipam is characterized in that the transaminase is whole cells of genetically engineered bacteria, broken enzyme solution, lyophilized powder, immobilized enzyme or immobilized cells, and tris(hydroxymethyl)aminomethane or any form of its salt, isopropylamine or any form of its salt, and pyridoxal phosphate need to be added during the reaction process.

[0037] The use of the transaminase in the synthesis of the key intermediate of Remigipam described in the present invention is characterized in that the substrate concentration in the reaction system is 5-20 g / L, the transaminase is an active broken enzyme solution, and the enzyme input amount is controlled to be 25-100 g / L.

[0038] The use of the transaminase in the synthesis of the key intermediate of Remigipam in the present invention is characterized in that the amount of trishydroxymethylaminomethane or any form of its salt added in the reaction system is 2.5 to 3.5 molar equivalents of the amount of the substrate; the amount of isopropylamine or any form of its salt added is 20 to 30 molar equivalents of the amount of the substrate; and the amount of pyridoxal phosphate added is 0.1 to 0.3 molar equivalents of the amount of the substrate.

[0039] The use of the transaminase in the synthesis of the key intermediate of Remigipam described in the present invention is characterized in that the pH value of the system is controlled within the range of 8.5 to 9.5 during the reaction.

[0040] The use of the transaminase in the synthesis of the key intermediate of Remigipam described in the present invention is characterized in that the reaction temperature is controlled within the range of 40° C. to 60° C. during the reaction process.

[0041] The use of the transaminase in the synthesis of the key intermediate of Remigipam described in the present invention is characterized in that the solvent of the reaction system is selected from water, a buffered aqueous solution, a mixed solvent system of water and dimethyl sulfoxide, a mixed solvent system of water and N,N-dimethylformamide, and a mixed solvent system of water and ethanol.

[0042] Compared with the prior art, the technical solution described in the present invention has the following advantages:

[0043] (1) The transaminase of the present invention has high stereoselectivity when synthesizing the key intermediate compound of formula I of Remigipan, and the de value of the target product can reach 99.96% (the de value of the prior art product I is only 99.5%);

[0044] (2) When the aminotransferase of the present invention is used to prepare the intermediate compound of formula I of Remegipam, the yield can reach more than 90% (the yield of the product I of the prior art is only 80%);

[0045] (3) The technology of preparing the intermediate compound of formula I of Remegipam by using transaminase of the present invention is green and environmentally friendly, with simple process and mild reaction conditions, avoiding the use of toxic and dangerous reagents; the preparation of chiral amine substances by using transaminase is low in cost and suitable for industrial production. BRIEF DESCRIPTION OF THE DRAWINGS

[0046] Figure 1 The HPLC purity of the concentrated solution of the compound of formula I prepared by the technical scheme described in the present invention; Figure 2 HPLC purity of the concentrated solution of chiral analogs of the compound of formula I prepared by chemical method; Figure 3 The HPLC purity of the compound of formula I prepared by the technical scheme described in the present invention; Figure 4 HPLC purity of chiral analogs of compounds of formula I prepared by chemical methods. DETAILED DESCRIPTION

[0047] The following specific embodiments are provided to enable those skilled in the art to fully understand the present invention, but are not intended to limit the present invention in any way.

[0048] In the following examples, unless otherwise specified, all temperatures are degrees Celsius; unless otherwise specified, the room temperature is 20-30°C; unless otherwise specified, various starting materials and reagents are commercially available and are used directly without further purification; unless otherwise specified, various solvents are industrial grade solvents and are used directly without further treatment; unless otherwise specified, commercial manufacturers include but are not limited to Hangzhou Chemical Reagent, Sinopharm Reagent, etc.

[0049] In the following examples, unless otherwise specified, the preparation of the enzyme mutants does not limit the scope of the present invention. The present invention only selects preferred embodiments for demonstration and does not mean that all related research works are limited to these.

[0050] In the following examples, unless otherwise specified, the detection method of the de value of the compound of formula I is based on the liquid chromatography detection method in patent CN115060824B.

[0051] In the following examples, unless otherwise specified, the liquid phase purity test method of the compound of formula I is carried out according to the following HPLC method and chromatographic conditions: Chromatographic column: Inertsustain AQ-C184.0 * 150mm, 3um or equivalent column; flow rate: 0.8mL / min; injection volume: 10μL; column temperature: 40℃; wavelength: 266nm; running time: 60min; mobile phase A: 0.1% trifluoroacetic acid water; mobile phase B: acetonitrile; elution gradient: 0→5min, mobile phase A: mobile phase B=95:5; 5→20min, mobile phase A: mobile phase B=95:5→60:40; 20→30min, mobile phase A: mobile phase B=60:40; 30→45min, mobile phase A: mobile phase B=60:40→15:85; 45→50min, mobile phase A: mobile phase B=15:85; 50→52min, mobile phase A: mobile phase B=15:85→95:5; 52→60min, mobile phase A: mobile phase B=95:5. Test solution: Accurately weigh 25 mg of the test sample, dissolve it in a 25 mL volumetric flask with 10% methanol and water and make up to the mark, then shake well.

[0052] In the following examples, unless otherwise specified, the liquid phase purity test method of the compound of formula V is carried out according to the following HPLC method and chromatographic conditions: Chromatographic column: Atlantis Prenier BEH C18AX 4.6 *150mm, 5um or equivalent column; Flow rate: 1.0mL / min; Injection volume: 10μL; Column temperature: 40℃; Wavelength: 260nm; Run time: 45min; Mobile phase A: 0.1% phosphoric acid water; Mobile phase B: acetonitrile; Elution gradient: 0→5min, mobile phase A: mobile phase B = 95:5; 5→25min, mobile phase A: mobile phase B = 95:5→15:85; 25→35min, mobile phase A: mobile phase B = 15:85; 35→35.01min, mobile phase A: mobile phase B = 15:85→95:5; 35.01→45min, mobile phase A: mobile phase B = 95:5. Test solution: Accurately weigh 25mg of the test sample, dissolve it in a 25mL volumetric flask with methanol and dilute to the mark, shake well.

[0053] In the following examples, unless otherwise specified, the molecular biology experiments including plasmid construction, enzyme digestion, competent cell preparation, transformation, etc. were mainly carried out with reference to Molecular Cloning Laboratory Manual (3rd edition), edited by J. Sambrook and DW Russell (USA), translated by Huang Peitang et al., Science Press, Beijing, 2002). If necessary, the specific experimental conditions can be determined by simple experiments.

[0054] Example 1: Technical solution for constructing transaminase described in the present invention

[0055] A. Construction of expression strains: Construction of recombinant E. coli of the transaminase described in the present invention: Aquamicrobium defluvii transaminase ADTA (amino acid sequence SEQ ID NO: 2) was selected as the source, codon optimization was performed in E. coli according to the amino acid sequence of SEQ ID NO: 1, the gene sequence of the transaminase described in the present invention was synthesized by full gene, and restriction endonuclease sites NdeI and BamHI were designed at both ends of the gene, subcloned into the corresponding sites of the vector pET-24a (+) (Novagen), and the recombinant plasmid pET24a-ADTA was obtained, and the E. coli expression host BL21 (DE3) was transformed to obtain the recombinant E. coli strain expressing the transaminase described in the present invention. The obtained strain was placed in a glycerol tube and frozen for standby use.

[0056] B. Preparation of the transaminase solution of the present invention:

[0057] (1) Materials and methods

[0058] LB medium: 10 g / L tryptone, 5 g / L yeast extract, 10 g / L sodium chloride, pH 7.2, sterilized at 121°C for 20 min;

[0059] TB medium: 24 g / L yeast extract, 12 g / L tryptone, 16.43 g / L K2HPO4·3H2O, 2.31 g / L KH2PO4, 5 g / L glycerol, pH 7.0-7.5, sterilized at 121°C for 20 min;

[0060] Slant culture medium: 10g / L tryptone, 5g / L yeast extract, 10g / L sodium chloride, 20g / L agar powder. Mix well and dispense into eggplant bottles according to 30-40mL of liquid. Place upright at 121℃ for high temperature and high pressure sterilization for 20min. After cooling, add 100μg / mL kanamycin sulfate, place into a slope, and wait for condensation into a solid.

[0061] (2) Fermentation culture:

[0062] Seed activation: Take 100 μL of the preservation solution from the glycerol preservation tube in step A above, apply it evenly on the slope of the eggplant bottle with an inoculation loop, and then place it in a 37°C incubator for overnight (18 h);

[0063] Seed culture: Take 100 mL of sterile water and introduce it into the eggplant bottle to make a bacterial suspension. Take 50 μL of the bacterial suspension and inoculate it into a 250 mL shake flask containing 50 mL of TB medium. Culture it at 30°C and 220 rpm for 16 h.

[0064] Fermentation: The primary seed culture solution was inoculated into a 5 L shake flask containing 1 L TB medium, cultured at 37 °C, 220 rpm for 4-6 h, then 0.3 mM IPTG was added and the temperature was lowered to 28 °C, and induced culture was carried out at 220 rpm for 12 h.

[0065] Bacteria collection: collect the fermentation liquid, centrifuge it at 4000rpm for 30min, discard the supernatant and collect the bacterial sludge, and store it in a -20℃ freezer.

[0066] (3) Preparation of original enzyme solution:

[0067] Weigh 5 g of transaminase ADTA bacterial sludge, add 20 mL of deionized water to resuspend, and then disrupt the cells by ultrasound. After the disrupted liquid is centrifuged at 12000 rpm for 10 min, the supernatant is taken, which is the transaminase enzyme solution of the present invention and is placed in an ice bath for use.

[0068] (4) Preparation of enzyme mutants

[0069] Error-prone PCR was used in combination with transformation test to improve enzyme activity by obtaining different mutants. The specific error-prone PCR method is as follows:

[0070] Using pET24a-ADTA as a template, error-prone PCR and large primer PCR techniques were used to construct a random mutant library. The primers were designed as follows:

[0071] Forward primer err-F: 5′-GTTTAACTTTAAGAAGGAGATATAC-3′;

[0072] Reverse primer err-R: 5′-CTTGTCGACGGAGCTCGAAT-3′.

[0073] The 100μL error-prone PCR reaction system includes: 50ng plasmid template, 0.2μM each of a pair of primers err-F and err-R, 1XTaq buffer, 0.2mM dGTP, 0.2mM dATP, 1mM dCTP, 1mM dTTP, 7mM MgCl2, (0.2mM, 0.3mM, 0.4mM) MnCl2, and 1U Taq.

[0074] PCR reaction conditions were: 95℃, 5min; 94℃30s, 55℃30s, 72℃1.5min, 40 cycles; 72℃10min. The 1.4kb random mutation fragment was recovered from gel as a large primer and KOD FX neo DNA polymerase was used for MegaPrimerPCR: 94℃, 2min, 68℃10min; 98℃10s, 55℃30s, 68℃3min, 25 cycles; 68℃10min.

[0075] DpnI was added to the PCR product and digested at 37°C to remove the plasmid template. After purification and recovery, it was transformed into competent E. coli BL21 (DE3) by electroporation. 1 mL of LB medium was added to 37°C for 1 h, and Kan plates were coated and cultured at 37°C overnight to obtain more than 10 4 The mutant strains are randomly mutanted according to the methods (3) and (4) above. The enzyme solution is then used for transformation test to screen mutants with high enzyme activity.

[0076] Mutants with improved enzyme activity were screened, and then error-prone PCR and screening were performed, and finally M1-M5 with significantly improved enzyme activity were obtained, a total of 5 mutations.

[0077] Example 2: Testing the conversion of the compound of formula II using the original enzyme solution described in the present invention

[0078] Add 3 mg Tris.HCl, 10 mg isopropylamine hydrochloride, 5 mg pyridoxal phosphate and 1 mL purified water to a 5 mL centrifuge tube. After fully oscillating on an oscillator, transfer 0.1 mL of 10% sodium hydroxide solution to the mixture. Add 10 mg of the compound of formula II and 1 mL of the original enzyme solution to the mixture. After fully oscillating on an oscillator, place the centrifuge tube in a constant temperature incubator. Adjust the temperature of the constant temperature incubator to 40-50°C and oscillate for 4-5 hours.

[0079] Remove the centrifuge tube from the incubator, add 2 mL of dichloromethane to quench the reaction, shake it thoroughly on an oscillator, and centrifuge it. Take 1 mL of the dichloromethane layer after centrifugation and test it by HPLC. The HPLC test results show that the substrate conversion rate is 50.9%, the product purity is 43.5%, and the 5R-amino chiral isomer is 7.79%.

[0080] Example 3: Testing the conversion of the compound of formula II using the mutant M1 described in the present invention

[0081] Add 3 mg Tris.HCl, 10 mg isopropylamine hydrochloride, 5 mg pyridoxal phosphate and 1 mL purified water to a 5 mL centrifuge tube. After fully oscillating on an oscillator, transfer 0.1 mL of 10% sodium hydroxide solution to the mixture. Add 10 mg of the compound of formula II and 1 mL of mutant M1 enzyme solution to the mixture. After fully oscillating on an oscillator, place the centrifuge tube in a constant temperature incubator. Adjust the temperature of the constant temperature incubator to 40-50°C and oscillate for 4-5 hours.

[0082] Remove the centrifuge tube from the incubator, add 2 mL of dichloromethane to quench the reaction, shake it thoroughly on an oscillator, and centrifuge it. Take 1 mL of the dichloromethane layer after centrifugation and test it by HPLC. The HPLC test results show that the substrate conversion rate is 53.0%, the product purity is 47.3%, and the 5R-amino chiral isomer is 5.77%.

[0083] Example 4: Testing the conversion of the compound of formula II using the mutant M2 described in the present invention

[0084] Add 3 mg Tris.HCl, 10 mg isopropylamine hydrochloride, 5 mg pyridoxal phosphate and 1 mL purified water to a 5 mL centrifuge tube. After fully oscillating on an oscillator, transfer 0.1 mL of 10% sodium hydroxide solution to the mixture. Add 10 mg of the compound of formula II and 1 mL of mutant M2 enzyme solution to the mixture. After fully oscillating on an oscillator, place the centrifuge tube in a constant temperature incubator. Adjust the temperature of the constant temperature incubator to 40-50°C and oscillate for 4-5 hours.

[0085] Remove the centrifuge tube from the incubator, add 2 mL of dichloromethane to quench the reaction, shake it thoroughly on an oscillator, and centrifuge it. Take 1 mL of the dichloromethane layer after centrifugation and test it by HPLC. The HPLC test results show that the substrate conversion rate is 57.1%, the product purity is 51.4%, and the 5R-amino chiral isomer is 2.96%.

[0086] Example 5: Testing the conversion of the compound of formula II using the mutant M3 described in the present invention

[0087] Add 3 mg Tris.HCl, 10 mg isopropylamine hydrochloride, 5 mg pyridoxal phosphate and 1 mL purified water to a 5 mL centrifuge tube. After fully shaking and mixing on an oscillator, transfer 0.1 mL of 10% sodium hydroxide solution to the mixture. Add 10 mg of the compound of formula II and 1 mL of mutant M3 enzyme solution to the mixture. After fully shaking and mixing on an oscillator, place the centrifuge tube in a constant temperature incubator. Adjust the temperature of the constant temperature incubator to 40-50°C and shake and culture for 4-5 hours.

[0088] Remove the centrifuge tube from the incubator, add 2 mL of dichloromethane to quench the reaction, shake it thoroughly on an oscillator, and centrifuge it. Take 1 mL of the dichloromethane layer after centrifugation and test it by HPLC. The HPLC test results show that the substrate conversion rate is 68.4%, the product purity is 63.3%, and the 5R-amino chiral isomer is 4.03%.

[0089] Example 6: Testing the conversion of the compound of formula II using the mutant M4 described in the present invention

[0090] Add 3 mg Tris.HCl, 10 mg isopropylamine hydrochloride, 5 mg pyridoxal phosphate and 1 mL purified water to a 5 mL centrifuge tube. After fully oscillating on an oscillator, transfer 0.1 mL of 10% sodium hydroxide solution to the mixture. Add 10 mg of the compound of formula II and 1 mL of mutant M4 enzyme solution to the mixture. After fully oscillating on an oscillator, place the centrifuge tube in a constant temperature incubator. Adjust the temperature of the constant temperature incubator to 40-50°C and oscillate for 4-5 hours.

[0091] Remove the centrifuge tube from the incubator, add 2 mL of dichloromethane to quench the reaction, shake it thoroughly on an oscillator, and centrifuge it. Take 1 mL of the dichloromethane layer after centrifugation and test it by HPLC. The HPLC test results show that the substrate conversion rate is 76.8%, the product purity is 72.5%, and the 5R-amino chiral isomer is 3.95%.

[0092] Example 7: Testing the conversion of the compound of formula II using the mutant M5 described in the present invention

[0093] Add 3 mg Tris.HCl, 10 mg isopropylamine hydrochloride, 5 mg pyridoxal phosphate and 1 mL purified water to a 5 mL centrifuge tube. After fully oscillating on an oscillator, transfer 0.1 mL of 10% sodium hydroxide solution to the mixture. Add 10 mg of the compound of formula II and 1 mL of mutant M5 enzyme solution to the mixture. After fully oscillating on an oscillator, place the centrifuge tube in a constant temperature incubator. Adjust the temperature of the constant temperature incubator to 40-50°C and oscillate for 4-5 hours.

[0094] Remove the centrifuge tube from the incubator, add 2 mL of dichloromethane to quench the reaction, shake it thoroughly on an oscillator, and centrifuge it. Take 1 mL of the dichloromethane layer after centrifugation and test it by HPLC. The HPLC test results show that the substrate conversion rate is 89.8%, the product purity is 88.9%, and the 5R-amino chiral isomer is 0.62%.

[0095] Example 8: Existing enzymatic technology described in the document Org.Process Res.Dev.2022,26,1971-1977

[0096] Add 40 mL of crude enzyme lysate, 46 mL of 6M i-PrNH2, 200 mg of pyridoxal phosphate and 104 mL of 0.1M Tris-HCl buffer solution (pH 9.0) to a 500 mL reaction bottle, and stir to dissolve all solids. Adjust the pH to 9.0 with 10% NaOH solution and adjust the reaction temperature to 45°C. Dissolve 4.0 g of compound II in 10 mL of dimethyl sulfoxide and slowly add to the reaction mixture. Control the pH of the reaction system to about 9.0 and stir the reaction for 74 hours.

[0097] After the reaction is completed, 36% hydrochloric acid is added to the reaction solution to adjust the pH value to 2-3, and then stirred at 25°C for 1 hour. The solution is mixed with diatomaceous earth as a filter aid, and most of the enzyme precipitate is removed by filtration. After the filtrate is rinsed with purified water, the pH value is adjusted to 10-11 with NaOH solution. Then, it is extracted three times with methyl tert-butyl ether, the organic phase is collected, and the resulting solution is concentrated to dryness under reduced pressure to obtain a concentrated solution of product I. The molar yield is 80.5%, the product purity is 99.8%, and the product de value is 99.5%.

[0098] Example 9: Technical solution for constructing chiral intermediates similar to Formula V-1 (patent WO2011046997A) using existing chemical technology

[0099]

[0100] 6.52 g of compound 1, 60 mL of 1,4-dioxane and 10 mL of tetraisopropyl titanate were added to a 100 mL autoclave reactor, purged with nitrogen and ammonia three times each, maintaining the ammonia pressure at 0.8 MPa, adjusting the reaction temperature to 50 ° C, and stirring the reaction for 20 hours. After the reaction, the mixture was cooled to 20 ° C, and then 1.5 g of 5% Pd / alumina was added, purged with nitrogen and hydrogen three times each, maintaining the hydrogen pressure at 0.8 MPa, and then heated to 50 ° C, and continued to stir the reaction for 23 hours.

[0101] After the reaction is completed, the reaction mixture is cooled to 20°C, filtered, and transferred to a 100mL three-necked flask. 10mL of water is added to the mixture, stirred, and filtered. The filter cake is then washed with 50mL of 1,4-dioxane, and the filtrate is concentrated to dryness under reduced pressure. The slurry is dissolved in 50mL of isopropanol, and 10.0mL of 5M hydrochloric acid isopropanol solution is added to the solution. Subsequently, 60mL of isopropyl acetate is added to the slurry, heated at 45°C for 10min, then cooled to 22°C and stirred for 3h, and dried to obtain 4.24g of white compound formula V-1 solid. The substrate conversion rate is 97.9%, and the molar yield is 55.8%. The product purity is 71.2%, 5R-amino chiral isomer is 11.12%, and the product de value is 72.99%.

[0102] Example 10: The technical solution described in the present invention (using the transaminase mutant M5)

[0103] Add 6.52g Tris.HCl, 33.0g isopropylamine hydrochloride, 0.51g pyridoxal phosphate and 300mL purified water to a 1000mL reaction bottle, stir and dissolve, adjust the pH of the mixture to 8.5-9.0 with 10% sodium hydroxide solution to obtain a buffer solution for standby use. Add 4.0g of the compound of formula II and 13.0g of the transaminase described in the present invention to the above reaction mixture, adjust the reaction temperature to 40-50°C, use 10% sodium hydroxide solution to maintain the pH value of the reaction system at 8.5-9.0, and stir the reaction for 20-24h.

[0104] After the reaction is completed, 250 mL of dichloromethane is added to the reaction solution, and the quenched solution is filtered through diatomaceous earth after stirring for 2.5 hours. The filtrate is washed with purified water, and the pH value of the filtrate is adjusted to 9.5 with 10% sodium hydroxide solution. Then, the mixture is extracted three times with methyl tert-butyl ether, and the organic phase is collected. The obtained solution is concentrated to dryness under reduced pressure at 40-50°C to obtain a concentrated solution.

[0105] Add 20 mL of isopropyl alcohol and 50 mL of isopropyl acetate to the concentrate, raise the temperature to 65-75°C, and drop 6.0 g of 20% hydrochloric acid isopropyl alcohol solution. After the dropwise addition is complete, cool to 0-15°C, and stir for 1 hour after cooling. Filter, rinse the filter cake with 20 mL of isopropyl acetate, and dry the filter cake at 45-55°C under reduced pressure to obtain 4.53 g of white solid compound of formula I. The substrate conversion rate is 99.9%, and the molar yield is 90.5%. The product purity is 99.7%, 5R-amino chiral isomer is 0.03%, and the product de value is 99.94%.

[0106] Example 11: Technical solution described in the present invention (using transaminase mutant M5)

[0107] Add 7.13g Tris.HCl, 36.5g isopropylamine hydrochloride, 0.55g pyridoxal phosphate and 300mL purified water to a 1000mL reaction bottle, stir and dissolve, adjust the pH of the mixture to 8.5-9.0 with 10% sodium hydroxide solution, and obtain a buffer for standby use. Add 4.1g of the compound of formula II and 15.0g of the transaminase described in the present invention to the above reaction mixture, adjust the reaction temperature to 45-50°C, use 10% sodium hydroxide solution to maintain the pH value of the reaction system at 8.5-9.0, and stir the reaction for 20-22h.

[0108] After the reaction is completed, 250 mL of dichloromethane is added to the reaction solution, and the quenched solution is filtered through diatomaceous earth after stirring for 2.5 hours. The filtrate is washed with purified water, and the pH value of the filtrate is adjusted to 9.5 with 10% sodium hydroxide solution. Then, the mixture is extracted three times with methyl tert-butyl ether, and the organic phase is collected. The obtained solution is concentrated to dryness under reduced pressure at 40-50°C to obtain a concentrated solution.

[0109] Add 20 mL of isopropyl alcohol and 50 mL of isopropyl acetate to the concentrate, raise the temperature to 65-75°C, and drop 6.15 g of 20% hydrochloric acid isopropyl alcohol solution. After the dropwise addition is complete, cool to 0-15°C, and stir for 1 hour after cooling. Filter, rinse the filter cake with 20 mL of isopropyl acetate, and dry the filter cake at 45-55°C under reduced pressure to obtain 4.73 g of white solid compound of formula I. The substrate conversion rate is 99.9%, and the molar yield is 92.2%. The product purity is 99.8%, 5R-amino chiral isomer is 0.02%, and the product de value is 99.96%.

[0110] Example 12: The technical solution described in the present invention (using the aminotransferase mutant M5)

[0111] Add 7.34g Tris.HCl, 46.1g isopropylamine hydrochloride, 0.85g pyridoxal phosphate and 300mL purified water to a 1000mL reaction bottle, stir and dissolve, adjust the pH of the mixture to 8.5-9.0 with 10% sodium hydroxide solution to obtain a buffer solution for standby use. Add 5.0g of the compound of formula II and 14.0g of the transaminase described in the present invention to the above reaction mixture, adjust the reaction temperature to 45-55°C, use 10% sodium hydroxide solution to maintain the pH value of the reaction system at 8.5-9.0, and stir the reaction for 20-24h.

[0112] After the reaction is completed, 250 mL of dichloromethane is added to the reaction solution, and the quenched solution is filtered through diatomaceous earth after stirring for 2.5 hours. The filtrate is washed with purified water, and the pH value of the filtrate is adjusted to 9.5 with 10% sodium hydroxide solution. Then, the mixture is extracted three times with methyl tert-butyl ether, and the organic phase is collected. The obtained solution is concentrated to dryness under reduced pressure at 40-50°C to obtain a concentrated solution.

[0113] Add 20 mL of isopropyl alcohol and 50 mL of isopropyl acetate to the concentrate, raise the temperature to 65-75°C, and drop 7.5 g of 20% hydrochloric acid isopropyl alcohol solution. After the dropwise addition is complete, cool to 0-15°C, and stir for 1 hour after cooling. Filter, rinse the filter cake with 20 mL of isopropyl acetate, and dry the filter cake at 45-55°C under reduced pressure to obtain 5.73 g of white solid compound of formula I. The substrate conversion rate is 99.8%, and the molar yield is 91.6%. The product purity is 99.6%, 5R-amino chiral isomer is 0.04%, and the product de value is 99.92%.

[0114] Example 13: Technical solution described in the present invention (using transaminase mutant M5)

[0115] Add 8.09g Tris.HCl, 41.13g isopropylamine hydrochloride, 0.74g pyridoxal phosphate and 300mL purified water to a 1000mL reaction bottle, stir and dissolve, and adjust the pH of the mixture to about 9.0 with 10% sodium hydroxide solution to obtain a buffer solution for standby use. Add 4.8g of the compound of formula II and 14.5g of the transaminase described in the present invention to the above reaction mixture, adjust the reaction temperature to 50-55°C, use 10% sodium hydroxide solution to keep the pH value of the reaction system at about 9.0, and stir the reaction for 22-24h.

[0116] After the reaction is completed, 250 mL of dichloromethane is added to the reaction solution, and the quenched solution is filtered through diatomaceous earth after stirring for 2.5 hours. The filtrate is washed with purified water, and the pH value of the filtrate is adjusted to 9.5 with 10% sodium hydroxide solution. Then, the mixture is extracted three times with methyl tert-butyl ether, and the organic phase is collected. The obtained solution is concentrated to dryness under reduced pressure at 40-50°C to obtain a concentrated solution.

[0117] Add 20 mL of isopropyl alcohol and 50 mL of isopropyl acetate to the concentrate, raise the temperature to 65-75°C, and drop 7.2 g of 20% hydrochloric acid isopropyl alcohol solution. After the dropwise addition is complete, cool to 0-15°C, and stir for 1 hour after cooling. Filter, rinse the filter cake with 20 mL of isopropyl acetate, and dry the filter cake at 45-55°C under reduced pressure to obtain 5.52 g of white solid compound of formula I. The substrate conversion rate is 99.8%, and the molar yield is 91.9%. The product purity is 99.8%, 5R-amino chiral isomer is 0.02%, and the product de value is 99.96%.

[0118] Example 14: The technical solution described in the present invention (using the aminotransferase mutant M5)

[0119] Add 4.56g Tris.HCl, 20.76g isopropylamine hydrochloride, 0.38g pyridoxal phosphate and 300mL purified water to a 1000mL reaction bottle, stir and dissolve, and adjust the pH of the mixture to about 9.0 with 10% sodium hydroxide solution to obtain a buffer solution for standby use. Add 3.0g of the compound of formula II and 13.0g of the transaminase described in the present invention to the above reaction mixture, adjust the reaction temperature to 50-60°C, use 10% sodium hydroxide solution to keep the pH value of the reaction system at about 9.0, and stir the reaction for 20-24h.

[0120] After the reaction is completed, 250 mL of dichloromethane is added to the reaction solution, and the quenched solution is filtered through diatomaceous earth after stirring for 2.5 hours. The filtrate is washed with purified water, and the pH value of the filtrate is adjusted to 9.5 with 10% sodium hydroxide solution. Then, the mixture is extracted three times with methyl tert-butyl ether, and the organic phase is collected. The obtained solution is concentrated to dryness under reduced pressure at 40-50°C to obtain a concentrated solution.

[0121] Add 20 mL of isopropyl alcohol and 50 mL of isopropyl acetate to the concentrate, raise the temperature to 65-75°C, and drop 4.5 g of 20% hydrochloric acid isopropyl alcohol solution. After the dropwise addition is complete, cool to 0-15°C, and stir for 1 hour after cooling. Filter, rinse the filter cake with 20 mL of isopropyl acetate, and dry the filter cake under reduced pressure at 45-55°C to obtain 3.39 g of white solid compound of formula I. The substrate conversion rate is 99.6%, and the molar yield is 90.3%. The product purity is 99.7%, 5R-amino chiral isomer is 0.05%, and the product de value is 99.90%.

[0122] Example 15: The technical solution described in the present invention (using the aminotransferase mutant M5)

[0123] Add 5.91g Tris.HCl, 26.1g isopropylamine hydrochloride, 0.34g pyridoxal phosphate and 300mL purified water to a 1000mL reaction bottle, stir and dissolve, and adjust the pH of the mixture to 9.0-9.5 with 10% sodium hydroxide solution to obtain a buffer solution for standby use. Add 3.3g of the compound of formula II and 18.0g of the transaminase described in the present invention to the above reaction mixture, adjust the reaction temperature to 50-60°C, use 10% sodium hydroxide solution to maintain the pH value of the reaction system at 9.0-9.5, and stir the reaction for 20-24h.

[0124] After the reaction is completed, 250 mL of dichloromethane is added to the reaction solution, and the quenched solution is filtered through diatomaceous earth after stirring for 2.5 hours. The filtrate is washed with purified water, and the pH value of the filtrate is adjusted to 9.5 with 10% sodium hydroxide solution. Then, the mixture is extracted three times with methyl tert-butyl ether, and the organic phase is collected. The obtained solution is concentrated to dryness under reduced pressure at 40-50°C to obtain a concentrated solution.

[0125] Add 20 mL of isopropyl alcohol and 50 mL of isopropyl acetate to the concentrate, raise the temperature to 65-75°C, and drop 4.95 g of 20% hydrochloric acid isopropyl alcohol solution. After the dropwise addition is complete, cool to 0-15°C, and stir for 1 hour after cooling. Filter, rinse the filter cake with 20 mL of isopropyl acetate, and dry the filter cake at 45-55°C under reduced pressure to obtain 3.86 g of white solid compound of formula I. The substrate conversion rate is 99.9%, and the molar yield is 93.4%. The product purity is 99.8%, 5R-amino chiral isomer is 0.05%, and the product de value is 99.90%.

[0126] Example 16: The technical solution described in the present invention (using the transaminase mutant M5)

[0127] Add 5.22g Tris.HCl, 21.1g isopropylamine hydrochloride, 0.27g pyridoxal phosphate and 300mL purified water to a 1000mL reaction bottle, stir and dissolve, adjust the pH of the mixture to 8.5-9.0 with 10% sodium hydroxide solution to obtain a buffer solution for standby use. Add 3.2g of the compound of formula II and 19.5g of the transaminase described in the present invention to the above reaction mixture, adjust the reaction temperature to 55-60°C, use 10% sodium hydroxide solution to maintain the pH value of the reaction system at 8.5-9.0, and stir the reaction for 23-24h.

[0128] After the reaction is completed, 250 mL of dichloromethane is added to the reaction solution, and the quenched solution is filtered through diatomaceous earth after stirring for 2.5 hours. The filtrate is washed with purified water, and the pH value of the filtrate is adjusted to 9.5 with 10% sodium hydroxide solution. Then, the mixture is extracted three times with methyl tert-butyl ether, and the organic phase is collected. The obtained solution is concentrated to dryness under reduced pressure at 40-50°C to obtain a concentrated solution.

[0129] Add 20 mL of isopropyl alcohol and 50 mL of isopropyl acetate to the concentrate, raise the temperature to 65-75°C, and drop 4.8 g of 20% hydrochloric acid isopropyl alcohol solution. After the dropwise addition is completed, cool to 0-15°C, and stir for 1 hour after cooling. Filter, rinse the filter cake with 20 mL of isopropyl acetate, and dry the filter cake under reduced pressure at 45-55°C to obtain 3.71 g of white solid compound of formula I. The substrate conversion rate is 99.8%, and the molar yield is 92.7%. The product purity is 99.7%, 5R-amino chiral isomer is 0.06%, and the product de value is 99.88%.

[0130] Example 17: The technical solution described in the present invention (using the aminotransferase mutant M5)

[0131] Add 7.01g Tris.HCl, 35.4g isopropylamine hydrochloride, 0.59g pyridoxal phosphate and 300mL purified water to a 1000mL reaction bottle, stir and dissolve, and adjust the pH of the mixture to 8.5-9.0 with 10% sodium hydroxide solution to obtain a buffer solution for standby use. Add 4.3g of the compound of formula II and 16.5g of the transaminase described in the present invention to the above reaction mixture, adjust the reaction temperature to 45-55°C, use 10% sodium hydroxide solution to maintain the pH value of the reaction system at 8.5-9.0, and stir the reaction for 23-24h.

[0132] After the reaction is completed, 250 mL of dichloromethane is added to the reaction solution, and the quenching solution is filtered through diatomaceous earth after stirring for 2.5 hours. After the filtrate is washed with purified water, the pH value of the filtrate is adjusted to 9.5 with 10% sodium hydroxide solution. Then it is extracted three times with methyl tert-butyl ether, the organic phase is collected, and the resulting solution is concentrated to dryness under reduced pressure at 40-50°C to obtain a concentrated solution, which is sampled for liquid phase purity detection. The substrate conversion rate is 99.6%, the product purity is 99.3%, the 5R-amino chiral isomer is 0.29%, and the product de value is 99.42%.

[0133] Example 18: The technical solution described in the present invention (using the aminotransferase mutant M5)

[0134] Add 8.31g Tris.HCl, 44.5g isopropylamine hydrochloride, 0.65g pyridoxal phosphate and 300mL purified water to a 1000mL reaction bottle, stir and dissolve, adjust the pH of the mixture to 9.0-9.5 with 10% sodium hydroxide solution to obtain a buffer solution for standby use. Add 4.5g of the compound of formula II and 21.3g of the transaminase described in the present invention to the above reaction mixture, adjust the reaction temperature to 45-55°C, use 10% sodium hydroxide solution to maintain the pH value of the reaction system at 9.0-9.5, and stir the reaction for 21-24h.

[0135] After the reaction is completed, 250 mL of dichloromethane is added to the reaction solution, and the quenching solution is filtered through diatomaceous earth after stirring for 2.5 hours. After the filtrate is washed with purified water, the pH value of the filtrate is adjusted to 9.5 with 10% sodium hydroxide solution. Then it is extracted three times with methyl tert-butyl ether, the organic phase is collected, and the resulting solution is concentrated to dryness under reduced pressure at 40-50°C to obtain a concentrated solution, which is sampled for liquid phase purity detection. The substrate conversion rate is 99.7%, the product purity is 99.2%, the 5R-amino chiral isomer is 0.22%, and the product de value is 99.56%.

[0136] Example 19: The technical solution described in the present invention (using the transaminase mutant M5)

[0137] Add 7.07g Tris.HCl, 36.0g isopropylamine hydrochloride, 0.64g pyridoxal phosphate and 300mL purified water to a 1000mL reaction bottle, stir and dissolve, and adjust the pH of the mixture to about 9.0 with 10% sodium hydroxide solution to obtain a buffer solution for standby use. Add 4.2g of the compound of formula II and 19.5g of the transaminase described in the present invention to the above reaction mixture, adjust the reaction temperature to 45-50°C, use 10% sodium hydroxide solution to keep the pH value of the reaction system at about 9.0, and stir the reaction for 21-24h.

[0138] After the reaction is completed, 250 mL of dichloromethane is added to the reaction solution, and the quenching solution is filtered through diatomaceous earth after stirring for 2.5 hours. After the filtrate is washed with purified water, the pH value of the filtrate is adjusted to 9.5 with 10% sodium hydroxide solution. Then it is extracted three times with methyl tert-butyl ether, the organic phase is collected, and the resulting solution is concentrated to dryness under reduced pressure at 40-50°C to obtain a concentrated solution, which is sampled for liquid phase purity detection. The substrate conversion rate is 99.9%, the product purity is 99.3%, the 5R-amino chiral isomer is 0.15%, and the product de value is 99.70%.

[0139] Example 20: The technical solution described in the present invention (using the aminotransferase mutant M5)

[0140] Add 9.86g Tris.HCl, 47.1g isopropylamine hydrochloride, 0.70g pyridoxal phosphate and 300mL purified water to a 1000mL reaction bottle, stir and dissolve, adjust the pH of the mixture to 8.5-9.0 with 10% sodium hydroxide solution to obtain a buffer solution for standby use. Add 5.5g of the compound of formula II and 22.5g of the transaminase described in the present invention to the above reaction mixture, adjust the reaction temperature to 45-50°C, use 10% sodium hydroxide solution to maintain the pH value of the reaction system at 8.5-9.0, and stir the reaction for 21-24h.

[0141] After the reaction is completed, 250 mL of dichloromethane is added to the reaction solution, and the quenching solution is filtered through diatomaceous earth after stirring for 2.5 hours. After the filtrate is washed with purified water, the pH value of the filtrate is adjusted to 9.5 with 10% sodium hydroxide solution. Then it is extracted three times with methyl tert-butyl ether, the organic phase is collected, and the resulting solution is concentrated to dryness under reduced pressure at 40-50°C to obtain a concentrated solution, which is sampled for liquid phase purity detection. The substrate conversion rate is 99.7%, the product purity is 99.2%, the 5R-amino chiral isomer is 0.25%, and the product de value is 99.50%.

[0142] Example 21: The technical solution described in the present invention (using the aminotransferase mutant M5)

[0143] Add 8.15g Tris.HCl, 49.4g isopropylamine hydrochloride, 0.61g pyridoxal phosphate and 300mL purified water to a 1000mL reaction bottle, stir and dissolve, adjust the pH of the mixture to 8.5-9.0 with 10% sodium hydroxide solution, and obtain a buffer for standby use. Add 6.0g of the compound of formula II and 30.0g of the transaminase described in the present invention to the above reaction mixture, adjust the reaction temperature to 50-60°C, use 10% sodium hydroxide solution to maintain the pH value of the reaction system at 8.5-9.0, and stir the reaction for 20-24h.

[0144] After the reaction is completed, 250 mL of dichloromethane is added to the reaction solution, and the quenching solution is filtered through diatomaceous earth after stirring for 2.5 hours. After the filtrate is washed with purified water, the pH value of the filtrate is adjusted to 9.5 with 10% sodium hydroxide solution. Then it is extracted three times with methyl tert-butyl ether, the organic phase is collected, and the resulting solution is concentrated to dryness under reduced pressure at 40-50°C to obtain a concentrated solution, which is sampled for liquid phase purity detection. The substrate conversion rate is 99.5%, the product purity is 99.0%, the 5R-amino chiral isomer is 0.31%, and the product de value is 99.38%.

[0145] Example 22: The technical solution described in the present invention (using the aminotransferase mutant M5)

[0146] Add 9.22g Tris.HCl, 43.7g isopropylamine hydrochloride, 0.77g pyridoxal phosphate and 300mL purified water to a 1000mL reaction bottle, stir and dissolve, adjust the pH of the mixture to 9.0-9.5 with 10% sodium hydroxide solution to obtain a buffer solution for standby use. Add 5.3g of the compound of formula II and 20.8g of the transaminase described in the present invention to the above reaction mixture, adjust the reaction temperature to 55-60°C, use 10% sodium hydroxide solution to maintain the pH value of the reaction system at 9.0-9.5, and stir the reaction for 22-24h.

[0147] After the reaction is completed, 250 mL of dichloromethane is added to the reaction solution, and the quenching solution is filtered through diatomaceous earth after stirring for 2.5 hours. After the filtrate is washed with purified water, the pH value of the filtrate is adjusted to 9.5 with 10% sodium hydroxide solution. Then it is extracted three times with methyl tert-butyl ether, the organic phase is collected, and the resulting solution is concentrated to dryness under reduced pressure at 40-50°C to obtain a concentrated solution, which is sampled for liquid phase purity detection. The substrate conversion rate is 99.7%, the product purity is 99.4%, the 5R-amino chiral isomer is 0.19%, and the product de value is 99.62%.

[0148] The method of the present invention is described by preferred embodiments. It is obvious that persons skilled in the relevant art can make appropriate common sense adjustments, changes and combinations to the methods and applications described in the present invention where necessary within the content and scope of the present invention to implement and apply the technology of the present invention. Personnel in the art can also refer to the content of the present invention and implement it by appropriately improving the process parameters. It is particularly important to point out that all similar improvements and adjustments are obvious to those skilled in the art and should be considered to be included in the present invention.

Claims

1. A transaminase, characterized in that The amino acid sequence is the protein shown in SEQ ID NO:

1.

2. The transaminase according to claim 1, characterized in that The transaminase encoding gene is the nucleotide sequence shown in SEQ ID NO:

2.

3. The recombinant expression vector, transgenic cell line or host bacteria of the transaminase encoding gene according to claim 1 or 2.

4. Use of the transaminase as claimed in claim 1 in the synthesis of a key intermediate of Remigipam.

5. The use of the transaminase according to claim 4 in the synthesis of a key intermediate of Remigipam, characterized in that: The method comprises the following steps: the compound of formula II is reacted under the action of transaminase to generate the compound of formula I, and the reaction formula is as follows:

6. The use of the transaminase according to claim 5 in the synthesis of a key intermediate of Remigipam, characterized in that: The transaminase is whole cells of genetically engineered bacteria, broken enzyme solution, freeze-dried powder, immobilized enzyme or immobilized cells. During the reaction, tris(hydroxymethyl)aminomethane or any salt thereof, isopropylamine or any salt thereof, and pyridoxal phosphate need to be added.

7. The use of the transaminase according to claim 5 in the synthesis of a key intermediate of Remigipam, characterized in that: The substrate concentration in the reaction system is 5-20 g / L, the transaminase is an active broken enzyme solution, and the enzyme input amount is controlled to be 25-100 g / L.

8. The use of the transaminase according to claim 5 in the synthesis of a key intermediate of Remigipam, characterized in that: The amount of tris(hydroxymethyl)aminomethane or any salt thereof added to the reaction system is 2.5-3.5 molar equivalents of the amount of the substrate; the amount of isopropylamine or any salt thereof added is 20-30 molar equivalents of the amount of the substrate; and the amount of pyridoxal phosphate added is 0.1-0.3 molar equivalents of the amount of the substrate.

9. The use of the transaminase according to claim 5 in the synthesis of a key intermediate of Remigipam, characterized in that: During the reaction, the pH value of the system is controlled within the range of 8.5 to 9.

5.

10. The use of the transaminase according to claim 5 in the synthesis of a key intermediate of Remigipam, characterized in that: During the reaction, the reaction temperature is controlled within the range of 40°C to 60°C.

11. The use of the transaminase according to claim 5 in the synthesis of a key intermediate of Remigipam, characterized in that: The solvent of the reaction system is selected from water, a buffered aqueous solution, a mixed solvent system of water and dimethyl sulfoxide, a mixed solvent system of water and N,N-dimethylformamide, and a mixed solvent system of water and ethanol.

Citation Information

Patent Citations

  • A liquid chromatography detection method for enantiomeric impurities of remigipam intermediates

    CN115060824B

  • Synthetic method of remegapam

    CN115677694A

  • Preparation method of iron catalyst and remegapam intermediate

    CN116768938A

  • CGRP receptor antagonists

    WO2011046997A1

  • Process for the preparation of cycloheptapyridine CGRP receptor antagonists

    WO2012050764A1

Cited By

  • (5S, 6S, 9R)-5-amino-6-(2, 3-difluorophenyl)-6, 7, 8, 9-tetrahydro-5H-cycloheptyl [b] pyridine-9-ol L-tartrate and preparation method thereof

    CN119977885A